The estimated Net Worth of Jean Pierre Bizzari is at least $6.44 Million dollars as of 17 June 2024. Jean Bizzari owns over 6,995 units of Halozyme Therapeutics stock worth over $4,721,624 and over the last 10 years he sold HALO stock worth over $1,455,566. In addition, he makes $260,002 as Independent Director at Halozyme Therapeutics.
Jean has made over 2 trades of the Halozyme Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 6,995 units of HALO stock worth $20,216 on 17 June 2024.
The largest trade he's ever made was selling 35,000 units of Halozyme Therapeutics stock on 25 August 2021 worth over $1,435,350. On average, Jean trades about 2,210 units every 54 days since 2015. As of 17 June 2024 he still owns at least 79,502 units of Halozyme Therapeutics stock.
You can see the complete history of Jean Bizzari stock trades at the bottom of the page.
Dr. Jean-Pierre Bizzari, M.D. is an Independent Director of the Company. Dr. Bizzari provides our Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012, and oversaw the development and approval of a number of leading oncology products including REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). Prior to 2008, Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek®(rasburicase). Dr. Bizzari was also Vice President, Clinical Development Oncology for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute (INCa) since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd., Pieris Pharmaceuticals, Inc. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and iTeos Therapeutics S.A, a biotechnology company. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.
As the Independent Director of Halozyme Therapeutics, the total compensation of Jean Bizzari at Halozyme Therapeutics is $260,002. There are 9 executives at Halozyme Therapeutics getting paid more, with Helen Torley having the highest compensation of $5,857,130.
Jean Bizzari is 65, he's been the Independent Director of Halozyme Therapeutics since 2015. There are 1 older and 9 younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics Inc. is Connie Matsui, 66, who is the Independent Chairman of the Board.
Over the last 18 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay, and Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: